安斯泰来制药的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 7 条
2023
2020
Astellas 就专利侵权起诉多家制药公司
提起诉讼
Astellas Pharma Inc. 及关联原告在特拉华州对 21 家制药公司提起诉讼。诉状指称，这些公司拟推出的 Myrbetriq 仿制药将侵犯 ’780 专利。原告请求法院给予救济。上述内容属于诉状中的指称，尚未被认定为事实。
Astellas Pharma Inc. 及关联原告在特拉华州起诉 21 家制药公司，指称其拟推出的 Myrbetriq 仿制药将侵犯 ’780 专利。原告请求法院给予救济；相关内容属于诉状中的指称。
来源摘录
At the District Court of Delaware on Tuesday, Astellas Pharma Inc. (API), Astellas Ireland Co. Ltd. (AICL), and Astellas Pharma Global Development (APGD) filed a complaint against 21 pharmaceutical companies alleging patent infringement.
The defendants are as follows: Sandoz Inc., Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA Inc., Apotex Inc., Apotex Corp., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Sawai Pharmaceutical Co. Ltd., Sawai USA Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Huahai US Inc., Solco Healthcare US LLC, Windlas Healthcare Pvt. Ltd., Windlas Biotech Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. (doing business as Zydus Cadila), Lupin Ltd., and Lupin Pharmaceuticals, Inc.
The patent in question, deemed the ’780 patent, corresponds to APGD’s Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.
2019
2018
2017
2016
2009